Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Income from Continuing Operations (2018 - 2025)

Serina Therapeutics' Income from Continuing Operations history spans 8 years, with the latest figure at 6398000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 20.08% year-over-year to 6398000.0; the TTM value through Sep 2025 reached 23396000.0, down 435.75%, while the annual FY2024 figure was 17574000.0, 376.65% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 6398000.0 at Serina Therapeutics, down from 5574000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7641000.0 in Q4 2023 and bottomed at 6398000.0 in Q3 2025.
  • The 5-year median for Income from Continuing Operations is 2507000.0 (2024), against an average of 2692473.68.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 376.85% in 2023 before it plummeted 296.3% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 2262000.0 in 2021, then decreased by 22.02% to 2760000.0 in 2022, then surged by 376.85% to 7641000.0 in 2023, then plummeted by 172.84% to 5566000.0 in 2024, then decreased by 14.95% to 6398000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Income from Continuing Operations are 6398000.0 (Q3 2025), 5574000.0 (Q2 2025), and 5858000.0 (Q1 2025).